0001562180-24-005567.txt : 20240703 0001562180-24-005567.hdr.sgml : 20240703 20240703075630 ACCESSION NUMBER: 0001562180-24-005567 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240701 FILED AS OF DATE: 20240703 DATE AS OF CHANGE: 20240703 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Simpson Curran CENTRAL INDEX KEY: 0001346164 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37553 FILM NUMBER: 241098264 MAIL ADDRESS: STREET 1: C/O REGENXBIO INC. STREET 2: 9804 MEDICAL CENTER DRIVE CITY: ROCKVILLE STATE: MD ZIP: 20850 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: REGENXBIO Inc. CENTRAL INDEX KEY: 0001590877 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 471851754 FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 9804 MEDICAL CENTER DRIVE CITY: ROCKVILLE STATE: MD ZIP: 20850 BUSINESS PHONE: 240-552-8181 MAIL ADDRESS: STREET 1: 9804 MEDICAL CENTER DRIVE CITY: ROCKVILLE STATE: MD ZIP: 20850 FORMER COMPANY: FORMER CONFORMED NAME: REGENXBIO, Inc. DATE OF NAME CHANGE: 20150116 FORMER COMPANY: FORMER CONFORMED NAME: ReGenX Biosciences, LLC DATE OF NAME CHANGE: 20131101 4 1 primarydocument.xml PRIMARY DOCUMENT X0508 4 2024-07-01 false 0001590877 REGENXBIO Inc. RGNX 0001346164 Simpson Curran C/O REGENXBIO INC. 9804 MEDICAL CENTER DRIVE ROCKVILLE MD 20850 true true false false Chief Executive Officer false Common Stock 2024-07-01 4 A false 56458.00 0.00 A 179785.00 D Stock Options (Right to Buy) 11.07 2024-07-01 4 A false 272189.00 0.00 A 2034-07-01 Common Stock 272189.00 272189.00 D The restricted stock unit (RSU) award vesting commencement date shall be July 1, 2024. 1/4th of the shares subject to the RSU shall vest on each of the first, second, third and fourth anniversaries of the first day of the month in which the RSU was granted, subject to the continuous service of the recipient to the Issuer. The option vesting commencement date shall be July 1, 2024. The options shall have a term of 10 years from the date of grant, subject to continuous service of the optionee to the Issuer. The options shall become exercisable as follows: with respect to 1/4th of the shares subject to the option when the optionee completes 12 months of continuous service to the Issuer after the vesting commencement date, and with respect to 1/48th of the shares subject to the option when the optionee completes each month of continuous service to the Issuer thereafter. /s/ Patrick J. Christmas as attorney-in-fact 2024-07-03